Cited 0 time in
Disease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Antao, Ainsley Mike | - |
| dc.contributor.author | Karapurkar, Janardhan Keshav | - |
| dc.contributor.author | Lee, Dong Ryul | - |
| dc.contributor.author | Kim, Kye-Seong | - |
| dc.contributor.author | Ramakrishna, Suresh | - |
| dc.date.accessioned | 2022-07-08T16:04:54Z | - |
| dc.date.available | 2022-07-08T16:04:54Z | - |
| dc.date.issued | 2020-01 | - |
| dc.identifier.issn | 2001-0370 | - |
| dc.identifier.issn | 2001-0370 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146359 | - |
| dc.description.abstract | CRISPR/Cas systems are popular genome editing tools that belong to a class of programmable nucleases and have enabled tremendous progress in the field of regenerative medicine. We here outline the structural and molecular frameworks of the well-characterized type II CRISPR system and several computational tools intended to facilitate experimental designs. The use of CRISPR tools to generate disease models has advanced research into the molecular aspects of disease conditions, including unraveling the molecular basis of immune rejection. Advances in regenerative medicine have been hindered by major histocompatibility complex-human leukocyte antigen (HLA) genes, which pose a major barrier to cell- or tissue-based transplantation. Based on progress in CRISPR, including in recent clinical trials, we hypothesize that the generation of universal donor immune-engineered stem cells is now a realistic approach to tackling a multitude of disease conditions. | - |
| dc.format.extent | 17 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER | - |
| dc.title | Disease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems | - |
| dc.type | Article | - |
| dc.publisher.location | 네델란드 | - |
| dc.identifier.doi | 10.1016/j.csbj.2020.11.026 | - |
| dc.identifier.scopusid | 2-s2.0-85096932517 | - |
| dc.identifier.wosid | 000607339100002 | - |
| dc.identifier.bibliographicCitation | COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, v.18, pp 3649 - 3665 | - |
| dc.citation.title | COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL | - |
| dc.citation.volume | 18 | - |
| dc.citation.startPage | 3649 | - |
| dc.citation.endPage | 3665 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
| dc.subject.keywordPlus | RNA-GUIDED ENDONUCLEASE | - |
| dc.subject.keywordPlus | OFF-TARGET | - |
| dc.subject.keywordPlus | IN-VIVO | - |
| dc.subject.keywordPlus | CYSTIC-FIBROSIS | - |
| dc.subject.keywordPlus | CRISPR-CAS9 NUCLEASES | - |
| dc.subject.keywordPlus | CRYSTAL-STRUCTURE | - |
| dc.subject.keywordPlus | GENETIC SCREENS | - |
| dc.subject.keywordPlus | T-LYMPHOCYTES | - |
| dc.subject.keywordPlus | SGRNA DESIGN | - |
| dc.subject.keywordPlus | DNA-REPAIR | - |
| dc.subject.keywordAuthor | CRISPR | - |
| dc.subject.keywordAuthor | Cas9 | - |
| dc.subject.keywordAuthor | HLA | - |
| dc.subject.keywordAuthor | Disease models | - |
| dc.subject.keywordAuthor | CAR T | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S2001037020304931?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
